NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Solventum Corporation SOLV
4 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$8.3B
▲ 0.9% vs FY2024
EPS · FY25
$8.88
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
38.9%
Net margin · FY25
18.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 8.3B
Revenue, FY2025 · full 4-year series below
Revenue
Net income
19 cents of every revenue dollar became profit this year.
Per share
USD 8.88
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
38.9%
Return on equity, FY2025
ROE
Operating margin26.2%
Net margin18.7%
Return on assets10.8%
Each USD of equity produced 39 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.8%
Net income
+5.0%
EPS, diluted
+4.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.17B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 14.3B
total assets, end of FY2025
Total assetsUSD 14.3B
EquityUSD 5.0B
CashUSD 878.0M
Gross debtUSD 5.0B
Net debtUSD 4.2B
Current ratio1.23×
Net debt stands at 82% of equity.
History
4 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
Revenue $B
8.3
8.3
8.2
8.1
Operating income $B
2.2
1.0
1.7
1.7
EBITDA $B
2.7
1.6
2.3
2.3
Income tax $B
0.2
0.1
0.3
0.3
Net income $B
1.6
0.5
1.3
1.3
EPS, diluted $
8.88
2.76
7.79
7.78
Dividend / sh $
·
·
·
·
Payout %
·
·
·
·
ROE %
38.9
6.6
11.5
11.4
Shares out B
0.17
0.17
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
10 of 10
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed